1. Hoy SM. Sodium Zirconium Cyclosilicate: A Review in Hyperkalemia. Drugs. 2018;78:1605-1613. https:doi.org/10.1007/s40265-018-0991-6.
2. Meaney CJ, Beccari MV, Yang Y, Zhao J. Systematic Review and Meta-Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia. Pharmacotherapy. 2017;37(4): 401–411. doi:10.1002/phar.1906.
3. Georgianos PI, Agarwal R. Revisiting RAAS blockade in CKD with newer potassium-binding drugs. Kidney Int. 2018;93(2):325–34. Doi: 10.1016/j.kint.2017.08.038.
4. Tamargo J, Caballero R, Delpón E. New therapeutic approaches for the treatment of hyperkalaemia in patients treated with renin-angiotensin-aldosterone system inhibitors. Cardiovasc Drugs Ther. 2018;32(1):99–119. Doi: 10.1007/s10557-017-6767-5.
5. Long B, Warix JR, Koyfman A. Controversies in management of hyperkalaemia. J Emerg Med. 2018;55(2):192–205. Doi: 10.1016/j.jemermed.2018.04.004.
6. Stavros F, Yang A, Leon A, et al. Characterization of structure and function of ZS-9, a K + selective ion trap. PLoS One. 2014;9(12):e114686. https://doi.org/10.1371/journal.pone.0114686
7. EMA. Lokelma (sodium zirconium cyclosilicate) for oral suspension: EU summary of product characteristics. 2018. http://www.ema.europ a.eu/ema/
8. FDA. Lokelma™ (sodium zirconium cyclosilicate) for oral suspension: US prescribing information. 2018. http://www.fda.gov/
9. Zannad F, Rasmussens HS, Lavin PT, et al. Zirconium cyclosilicate (ZS-9) on aldosterone from the phase 3 randomized, double-blind, placebo-controlled HARMONIZE study [abstract no. P1592]. Eur J Heart Fail. 2015;17(Suppl.):342. https: //doi.org/10.1002/ejhf.277
10. EMA. Sodium zirconium cyclosilicate: EU assessment report. 2018. http://www.ema.europ a.eu/ema/.
11. Ash SR, Singh B, Lavin PT, et al. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient. Kidney Int. 2015;88(2):404–11. Doi: 10.1038/ki.2014.382.
12. Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med. 2015;372(3):222–31. Doi:10.1056/NEJMoa1411487.
13. Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA. 2014;312(21):2223–33. Doi: 10.1001/jama.2014.15688, Erratum in: JAMA.2015 Feb 3;313(5):526.
14. Anker SD, Kosiborod M, Zannad F, et al. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail. 2015;17(10):1050–6. Doi:10.1002/ejhf.300
15. Kosiborod M, McCullough PA, Rasmussen H, et al. Acute efficacy of sodium zirconium cyclosilicate (ZS-9) in patients on mineralocorticoid-receptor antagonists: analysis from two phase 3 studies. Circulation 2015;132(Suppl 3). https://doi.org/10.1161/circ.132.suppl_3.13555
16. US National Institutes of Health. ClinicalTrials.gov identifier NCT02107092. 2016. http://clinicaltrials.gov/
17. Spinowitz BS, Fisbane S, Pergola PE, et al. Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12 –month Phase 3 study. Clin J Am Soc Nephrol. 2019;14(6):798-809. Doi: 10.2215/ CJN.12651018.
18. Roger S, Lavin P, Lemma E, et al. Safety and efficacy of sodium zirconium cyclosilicate for long-term treatment of hyperkalaemia in patients with chronic kidney disease: results from an open-label, phase 3 study [abstract no. FP071]. Nephrol Dial Transplant. 2018;33(Suppl 1):i72. https://doi.org/10.1093/ndt/gfy104.FP071
19. Fishbane S, Roger S, Packham D, et al. Sodium zirconium cyclosilicate for hyperkalaemia in patients with diabetes mellitus: retrospective analysis of a 12 month open label, phase 3 study [abstract no. SP421]. Nephrol Dial Transplant. 2018;33(Suppl1):i489–90. https://doi.org /10.1093/ ndt/gfy104.SP421.
20. McCullough P, Pergola P, Fishbane S, et al. Efficacy and safety of sodium zirconium cyclosilicate to treat hyperkalaemia among patients taking renin-angiotensin-aldosterone system inhibitors in a 12-month open-label, phase 3 study: a post hoc subgroup analysis [abstract no. 16610]. Circulation. 2017;136(Suppl 1):A16610.
21. Yoo N, Song YB, Dubinsky I, Altshuler J. Single Dose of Sodium Zirconium Cyclosilicate versus Sodium Polystyrene Sulfonate in Hospitalized Patients with Hyperkalemia. Ann Pharmacother. 2023;57(9):1044-1052. Doi: 10.1177/10600280221141918.
22. Sullivan E, Ruegger M, Dunne I, Sutaria N, Towers WF. Comparison of effectiveness and safety of sodium polystyrene sulfonate and sodium zirconium cyclosilicate in hospitalized patients. Am J health Syst Pharm.2023;80*18):1238-1246. Doi: 10.1093/ajhp/zxad137.
23. Hasara S, Dubey J, Amatea J, Finnigan N. Sodium polystyrene sulfonate versus sodium zirconium cyclosilicate for the treatment of hyperkalemia in the emergency department. Am J Emerg Med. 2023 Mar;65:59-64. doi:10.1016/j.ajem.2022.12.043.
24. Yang J, Guo Y, Chen S, et al. SZC and SPS, which is Better on Hyperkalemia in Dialysis Patients: A Retrospective Study. Research Square. 2023. DOI:10.21203/rs.3.rs-2919034/v1.
25. Joyce O, Corpman M. Comparison of Sodium Zirconium Cyclosilicate to Sodium Polystyrene Sulfonate in the Inpatient Management of Acute Hyperkalemia. J Pharm Pract. 2024;37(3):728-735. DOI:10.1177/0897 1900231176462.
26. Yao L, Xing X, Li Y, et al. Effects of different potassium-lowering regimens on acute hyperkalemia in hemodialysis patients: a real-world, retrospective study. J Transl Med. 2022;20(1):333. DOI:10.1186/s12967-022-03530-4.
27. Nakayama T, Tamaguchi S, Hayashi K et al. Compared effectiveness of sodium zirconium cyclosilicate and calcium polystyrene sulfonate on hyperkalemia in patients with chronic kidney disease. Front Med (Lausanne). 2023;10:1137981. doi:10.3389/fmed.2023.1137981
28. Shrestha DB, Budhatoki P, Sedhai YR et al. Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia A Systematic Review and Meta-Analysis. Curr Ther Res Clin Exp. 2021;95:100635. https://doi.org/10.1016/j.curtheres. 2021.100635.
29. Rydell A, Thackrey C, Molki M, Mullins BP. Effectiveness of Patiromer Versus Sodium Zirconium Cyclosilicate for the Management of Acute Hyperkalemia. Ann Pharmacother. 2024;58(8):790-795. Doi:10.1177/10600280231209968.
30. Ramirez de Arellano A, Jakutis G, Hunt B. Cost analysis of patiromer vs sodium zirconium cyclosilicate for the treatment of hyperkalemia in Spain and the UK. J Med Econ. 2024;27(1):1011-1017. https://doi.org/10.1080/13696998.2024.2382033
31. Fernandez-Prado R, Villalvazo P, Avello A, et al. Sodium zirconium cyclosilicate and metabolic acidosis: Potential mechanisms and clinical consequences. Biomed Pharmacother. 2023;158:114197. https://doi.org/10.1016/j.biopha.2022.114197.
32. Någård M, Singh B, Boulton DW. Effects of sodium zirconium cyclosilicate on sodium and potassium excretion in healthy adults: a Phase 1 study. Clin Kidney J. 2020 Dec 13;14(8):1924-1931. doi: 10.1093/ckj/sfaa237.
Facebook
Masuk dengan Email
